Stockscreener 앱 받기
0.8526
12.15%
-0.1179
시장 영업 전:
.75
-0.1026
-12.03%
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
What's going on with AIM ImmunoTech stock Friday? - MSN
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Why did AIM stock more than double in pre-market today? - MSN
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Sahm
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress - International Business Times
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAIM ImmunoTech (AMEX:AIM), Almonty Indus (NASDAQ:ALM) - Benzinga
AIM ImmunoTech Inc. (AIM) Latest Stock News & Headlines - Yahoo Finance
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatme - GuruFocus
Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech (AIM) Stock Soars Nearly 100% on Japanese Cancer Treatment Patent Approval - MEXC
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment - MEXC
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer - GlobeNewswire
AIM ImmunoTech Expands Cancer Drug Trials with Key Collaboration - StocksToTrade
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial - timothysykes.com
Patent Approval Drives Stock Price Surge: AIM ImmunoTech Inc. (AIM) shares soared 88% in pre-market trading today, reaching $1.34 - Bitget
Why Is AIM ImmunoTech Stock (AIM) Up Today? - TipRanks
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Bitget
Why Did AIM Stock More Than Double In Pre-Market Today? - Asianet Newsable
Patent Implementation and Core Therapy: AIM ImmunoTech Inc. announces that its innovative cancer therapy patent combining Ampligen with immune checkpoint inhibitors has received final approval in Japan - Bitget
AIM ImmunoTech announces final approval of novel cancer therapy patent in Japan combining Ampligen with checkpoint inhibitors - marketscreener.com
Aim Immunotech Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors - TradingView
AIM ImmunoTech (AIM) CEO converts Series G preferred into 25,000 common shares - Stock Titan
AIM ImmunoTech (AIM) director converts Series G preferred into 25,000 shares - Stock Titan
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech (AIM) director gets Series G preferred and 50,000 warrants - Stock Titan
AIM ImmunoTech Inc. Signs Dealer-Manager Agreement with Maxim Group LLC for Rights Offering – SEC Form 8-K Filing March 2026 - Minichart
AIM ImmunoTech completes rights offering, creates new preferred stock series By Investing.com - Investing.com Australia
Cancer-drug developer AIM ImmunoTech draws $1.8M in $1,000 rights sale - Stock Titan
AIM ImmunoTech Announces Closing of its Rights Offering - Caledonian Record
AIM ImmunoTech Completes Series G Preferred Rights Offering - TipRanks
AIM ImmunoTech completes rights offering, creates new preferred stock series - Investing.com
AIM ImmunoTech Appoints Equiniti as Warrant Agent for $1.8 Million Rights Offering - TradingView
AIM ImmunoTech (NYSE: AIM) raises $1.8M, issues Series G preferred and warrants - Stock Titan
Advance Information Marketing Bhd. (AIM) - Minichart
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Bitget
AIM ImmunoTech (AIM) Projects $1.8M from Rights Offering - GuruFocus
Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million - TradingView
AIM ImmunoTech raises $1.8M with $1,000 preferred stock and warrant bundles - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire
AIM Collaborates with Thermo Fisher for Phase 3 Trial of Amplige - GuruFocus
AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer. - Bitget
Experimental pancreatic cancer drug Ampligen moves toward Phase 3 test - Stock Titan
1.82%
자본화:
|
볼륨(24시간):